EUVIMEDEUVIMED entdecken
Crossref

Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022

Sofie Seghers iD, Pablo Mandó iD, Marc Eid iD, Charles J Tan iD, Aarthi Jayraj iD, Karan Jatwani, Muhammad Salman Faisal iD, Vi Luong iD, Joanna A Young iD, Laure-Anne Teuwen iD, Hans Prenen iD, Eva Segelov iD

JCO Oncology Practice · 2025

DOI: 10.1200/op-24-00739 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Sofie Seghers und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Antwerp University Hospital, Edegem, Belgium. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Medical Oncology, Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the ASCO Value Framework (ASCO-VF) are tools designed to assess the value of anticancer therapies. International conferences are the primary venues for sharing trial outcomes, often influencing clinical practices even before full publications are available. This analysis compares the ESMO-MCBS and ASCO-VF in evaluating the benefit of all phase III trials presented at the 2022 ASCO Annual Meeting (AM) and to examine the level of agreement between these scales. METHODS A systematic search of abstracts from the 2022 ASCO AM was conducted, focusing on phase III trial data presented. The clinical benefit of each abstract was assessed using both ESMO-MCBS and ASCO-VF, and Cohen's κ coefficients were calculated to analyze concordance between the tools. RESULTS Out of 239 phase III trial abstracts, 90 trials involving 49,721 patients met the inclusion criteria. Of these, 36 (40%) could not be graded by ESMO-MCBS, mainly because of nonsignificant results. Among the 54 gradable abstracts, 61.1% (n = 33) were deemed to provide substantial clinical benefit. ASCO-VF was unable to grade 40 (44.4%) abstracts, with nonsignificant results being the leading cause. Of the 50 gradable abstracts, 20% (n = 10) were considered to offer substantial clinical benefit. Moderate agreement between ESMO-MCBS and ASCO-VF was observed (Cohen's kappa, 0.4783 [95% CI, 0.3673 to 0.6034]). No significant association was found between clinical benefit and research funding or the economic status of the trial's origin country. CONCLUSION Both frameworks showed a high rate of nongradable studies, primarily because of nonsignificant results. ESMO-MCBS identified more studies with substantial clinical benefit, and the agreement between the two tools was moderate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicMedical OncologyNeoplasmsHumansSocieties, MedicalCongresses as TopicEurope

Autor:innen und Institutionen

  • Department of Oncology, Antwerp University Hospital, Edegem, Belgium.
  • Center for Oncologic Research (CORE), University of Antwerp, Wilrijk, Belgium.
  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina.
  • Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
  • Cancer Institute, St Luke's Medical Center, Quezon City, Philippines.
  • James Cook University Hospital, South Tees NHS Foundation Trust, Middlesbrough, United Kingdom.

ORCID-Profile: Sofie Seghers, Pablo Mandó, Marc Eid, Charles J Tan, Aarthi Jayraj, Muhammad Salman Faisal, Vi Luong, Joanna A Young, Laure-Anne Teuwen, Hans Prenen, Eva Segelov

Zitieren

APA

Seghers, S., Mandó, P., Eid, M., Tan, C. J., Jayraj, A., Jatwani, K., Faisal, M. S., Luong, V., Young, J. A., Teuwen, L. A., Prenen, H., & Segelov, E. (2025). Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022. JCO Oncology Practice. https://doi.org/10.1200/op-24-00739

Vancouver

Seghers S, Mandó P, Eid M, Tan CJ, Jayraj A, Jatwani K, et al. Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022. JCO Oncology Practice. 2025. doi:10.1200/op-24-00739

BibTeX
@article{Seghers2025,
  author = {Seghers, Sofie and Mandó, Pablo and Eid, Marc and Tan, Charles J and Jayraj, Aarthi and Jatwani, Karan and Faisal, Muhammad Salman and Luong, Vi and Young, Joanna A and Teuwen, Laure-Anne and Prenen, Hans and Segelov, Eva},
  title = {Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022},
  journal = {JCO Oncology Practice},
  year = {2025},
  doi = {10.1200/op-24-00739}
}
Kostenlos starten →